Q3 Earnings Alert! Plan early for this week’s stock reports with all key data in 1 placeSee list

Halozyme Therapeutics Inc (HALO)

NASDAQ
Currency in USD
Disclaimer
52.28
+0.15(+0.29%)
Real-time Data
HALO Scorecard
Full Analysis
Has a perfect Piotroski Score of 9
Fair Value
Day's Range
52.1652.64
52 wk Range
32.8365.53
Prev. Close
52.13
Open
52.26
Day's Range
52.16-52.64
52 wk Range
32.83-65.53
Volume
81,686
Average Volume (3m)
1,366,509
1-Year Change
39.72%
Book Value / Share
Unlock
Fair Value
Unlock
Fair Value Upside
Unlock
HALO Scorecardpro icon
Company’s Health
pro lockUnlock
Fair Value
pro lockUnlock Price
Fair Pricepro lock
Upsidepro lock
Price Target
61.70
Upside
+18.02%
Members' Sentiments
Bearish
Bullish
ProTips
Management has been aggressively buying back shares
Show more

Halozyme Therapeutics Inc Company Profile

Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company’s products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; rilpivirine, cabotegravir, and N6LS BNAB for the treatment of HIV; ocrelizumab for multiple sclerosis; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of chronic lymphocytic leukemia; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergic reactions; nivolumab+relatlimab and ANTI-TIM3 for the treatment of solid tumors; ARGX-117 for multifocal motor neuropathy; atezolizumab; nivolumab; afgartigimod; teriparatide injections; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.

Compare HALO to Peers and Sector

Metrics to compare
HALO
Peers
Sector
Relationship
P/E Ratio
19.7x−0.9x−0.6x
PEG Ratio
0.380.060.00
Price/Book
23.0x3.0x2.6x
Price / LTM Sales
7.6x18.4x3.2x
Upside (Analyst Target)
20.9%469.6%48.5%
Fair Value Upside
Unlock19.0%7.8%Unlock

People Also Watch

254.76
POWL
+3.13%
413.13
FIX
+1.43%
21.86
TGTX
+0.11%
356.30
UTHR
+0.56%
133.09
CAVA
+2.19%

FAQ

What Is the Halozyme (HALO) Stock Price Today?

The Halozyme stock price today is 52.28

What Stock Exchange Does Halozyme Trade On?

Halozyme is listed and trades on the NASDAQ stock exchange.

What Is the Stock Symbol for Halozyme?

The stock symbol for Halozyme is "HALO."

What Is the Halozyme Market Cap?

As of today, Halozyme market cap is 6.62B.

What is Halozyme Earnings Per Share?

The Halozyme EPS is 2.62.

What Is the Next Halozyme Earnings Date?

Halozyme will release its next earnings report on 03 Nov 2024.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.